A Case of Ocular Benign Lymphoid Hyperplasia Treated with Bevacizumab Injection.
- Author:
Doo Hwan OH
1
;
Yeoun Sook CHUN
;
Jae Chan KIM
Author Information
- Publication Type:Case Report
- Keywords: Bevacizumab; Conjunctival benign lymphoid hyperplasia; Subconjunctival injection
- MeSH: Adult; Angiogenesis Inhibitors/*administration & dosage; Antibodies, Monoclonal/*administration & dosage; Conjunctiva; Conjunctival Diseases/*drug therapy/*pathology; Humans; Hyperplasia; Injections, Intraocular; Limbus Corneae/blood supply; Lymphoid Tissue/*pathology; Lymphoproliferative Di; Male; Neovascularization, Pathologic/drug therapy
- From:Korean Journal of Ophthalmology 2011;25(1):57-59
- CountryRepublic of Korea
- Language:English
- Abstract: We report the first case of ocular benign lymphoid hyperplasia (BLH) treated with subconjunctival injection of bevacizumab (Avastin). A 27-year-old man presented to our clinic with conjunctival masses and limbal neovascularization. An incisional biopsy yielded the diagnosis of BLH. The patient was subsequently given a subconjunctival injection of bevacizumab (1.25 mg / 0.1 mL). The patient did not experience recurrence or malignant metaplasia during the one-year follow-up period. In patients with conjunctival BLH, subconjunctival injection of bevacizumab can be a useful treatment option in patients unable to undergo a surgical procedure due to limbal neovascularization.
